These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 32592711)

  • 1. Selective application of neuroendocrine markers in the diagnosis and treatment of small cell lung cancer.
    Du J; Li Y; Wang L; Zhou Y; Shen Y; Xu F; Chen Y
    Clin Chim Acta; 2020 Oct; 509():295-303. PubMed ID: 32592711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
    Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W
    Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer.
    Bi H; Yin L; Fang W; Song S; Wu S; Shen J
    Lab Med; 2023 Jul; 54(4):372-379. PubMed ID: 36282321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China.
    Wu XY; Hu YB; Li HJ; Wan B; Zhang CX; Zhang B; Hu H; Zhang Q; Lv TF; Zhan P; Song Y
    J Cell Mol Med; 2018 Sep; 22(9):4328-4334. PubMed ID: 29989303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Utility of NSE, ProGRP and LDH in Diagnosis and Treatment
in Patients with Small Cell Lung Cancer].
    Peng Y; Wang Y; Li J; Hao X; Hu X
    Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):590-4. PubMed ID: 27666548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the diagnostic and prognostic value of serum TuM2-PK, NSE, and ProGRP in small cell lung cancer.
    Li L; Zhang Q; Wang Y; Xu C
    J Clin Lab Anal; 2023 Apr; 37(7):e24865. PubMed ID: 37088873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic value of serum tumor markers CEA, CYFRA21-1, SCCAg, NSE and ProGRP for lung cancers of different pathological types].
    Gao J; Zhang L; Peng K; Sun H
    Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jun; 42(6):886-891. PubMed ID: 35790439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC).
    Shibayama T; Ueoka H; Nishii K; Kiura K; Tabata M; Miyatake K; Kitajima T; Harada M
    Lung Cancer; 2001 Apr; 32(1):61-9. PubMed ID: 11282430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Value and Clinical Significance of Combined Detection of Serum Markers CYFRA21-1, SCC Ag, NSE, CEA and ProGRP in Non-Small Cell Lung Carcinoma.
    Li Q; Sang S
    Clin Lab; 2020 Nov; 66(11):. PubMed ID: 33180443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic and prognostic value of ProGRP in lung cancer.
    Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
    Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations.
    Trulson I; Klawonn F; von Pawel J; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S81-S98. PubMed ID: 38277317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
    Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
    Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
    Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
    Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement.
    Yamaguchi K; Aoyagi K; Urakami K; Fukutani T; Maki N; Yamamoto S; Otsubo K; Miyake Y; Kodama T
    Jpn J Cancer Res; 1995 Jul; 86(7):698-705. PubMed ID: 7559089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer.
    Huang Z; Xu D; Zhang F; Ying Y; Song L
    Clin Transl Oncol; 2016 Oct; 18(10):1019-25. PubMed ID: 26886220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion].
    Liu YQ; Zhang HL; Gao WJ; Lan X; Yuan BJ; Zou JM
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan; 26(1):34-8. PubMed ID: 18302890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?
    Li M; Zhang Y; Jiang L; Li Y; Li G; Zhou J; Yang C; Li X; Qu W; Chen Y; Chen Q; Wang S; Xing J; Huang H
    Neoplasma; 2022 May; 69(3):729-740. PubMed ID: 35471981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.